Boardroom Alpha Digest: Thurs, Feb 23

by | Feb 23, 2023

Executive News

  • Foot Locker (FL) named Robert Higginbotham as interim CFO following the departure of Andrew Page, who the company terminated “without cause under the terms of his employment arrangement and the Company’s benefit plans”
  • Gregory D. Smith, former CEO of Boeing, will assume the role of Chairman of American Airlines (AAL) following former AAL CEO Doug Parker’s retirement from the board.
  • Belden Inc. (BDC) named Ashish Chand as its new CEO taking over from Roel Vestjens who resigned


  • Dan Loeb and Third Point have positioned that they intend to launch a proxy fight at Bath and Body Works (BBWI), and plans to nominate a shareholder nominee to the company’s board

IPOs Upcoming

  • NYIX, INC. (NYX) is expected to price ~$9-10M IPO at $5 per share on 2/24
  • NAVA HEALTH MD, LLC (NAVA) is looking to price $8.1M at $6 per share on 2/28


  • Insurers are said to receive a small win in the Social Capital Hedosophia Holdings III / Clover Health (CLOV) SPAC D&O Case
  • Decarbonization Plus Acquisition Corp. IV (DCRD) and Hammerhead Resources finally closed their business combination, and shares will trade as HHRS on Monday, 2/27
  • Warburg Pincus is shutting down their SPACs as both I-A and 1-B will liquidate

SPAC Calendar

<a href="" target="_self">David Drapkin</a>

David Drapkin

Spent his formative years at Goldman Sachs and now embraces the start-up life in NYC. A long suffering Oakland (Las Vegas) Raiders fan and graduate of the Wharton School at the University of Pennsylvania. Semi-professional go-kart racer waiting for his shot.

Know Who Drives Return

Objective, data-driven assessments for every public company director and officer.

SPAC Analytics & Database

Comprehensive research and analytics on every SPAC, sponsor, and deal. Real-time alerts, yields, red flags, filings, investors, and much more. API access to institutional grade SPAC database.

Monthly SPAC Review

SPAC Market Review – January 2023

It was a slower month to kick off the year for SPACs. In what stands to be a pivotal year for the future of the market, we recap January.

SPAC Market Review – December 2022

December’s SPAC market review takes a look by the numbers of the month’s SPAC activity and how the market currently stands going into 2023.

SPAC Research & Analysis

Boardroom Alpha Digest: Thurs, Mar 9

Biogen Inc. (BIIB) chairman Stelios Papadopoulos will not stand for reelection at the annual meeting, and other highlights of the day.

Boardroom Alpha Digest: Weds, Mar 1

Salesforce Inc. (CRM) surges after hours following earnings amidst potential activist activity and today’s SPAC, IPO, and Exec News.

Boardroom Alpha Digest: Thurs, Feb 9

Nelzon Peltz and Trian dropped their proxy fight against Walt Disney Co. (DIS) following Disney’s cost cutting, reorg, and board appointments.

Know Who Drives Return Podcast


The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon. 

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.  

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by BA that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.  

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.